Brandenburg Kapital - News about Adrenomed AG
Adrenomed announces positive trial results with antibody Adrecizumab in Septic Shock
Potsdam/Hennigsdorf - February 2020. Adrenomed AG, a pharmaceutical company focused on restoring the vascular integrity of blood vessels announced on February 21st 2020, the positive top-line results of the phase II proof-of-concept trial, titled AdrenOSS-2 trial in septic shock. In this trial involving 301 patients, the vaso-stabilizing antibody Adrecizumab was confirmed to be safe and well tolerated. Therewith the trial met the primary endpoint.
These positive data demonstrate an important step towards the development of the drug candidate. Detailed data from the AdrenOSS-2 trial will be submitted for publication in a peer-reviewed journal later this year.
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
For further information, please visit www.adrenomed.com and www.brandenburg-kapital.de